Drug · DIN 02536455
SPEVIGO
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 26, 2026; first marketed May 11, 2023.
- Drug Identification Number (DIN)
- 02536455
- Company (DIN owner)
- Leo Pharma IncToronto, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Spesolimab L04AC22
- Class
- Human
- Record last updated
- April 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SPESOLIMAB | 60 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 26, 2026: NOC 37202New Drug Submission (NDS) · Change in product ownership
- March 22, 2023: NOC 30360New Drug Submission (NDS)
Other DINs named SPEVIGO
- DIN 02550296 · Marketed
- DIN 02561697 · Approved